CRISPR Therapeutics News

CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note

Yahoo FinanceApr 26 17:50 ET

Buy Rating on Crispr Therapeutics AG Backed by Exa-cel's Precision and Favorable Safety Profile

TipRanksApr 26 02:24 ET

Regeneron to Collaborate on Gene Editing Therapies With Doudna-founded Mammoth

Yahoo FinanceApr 25 07:00 ET

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why

Yahoo FinanceApr 22 18:00 ET

Cathie Wood's Latest Stock Portfolio: Top 10 Stock Picks

Yahoo FinanceApr 22 12:49 ET

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious di

CRISPR TherapeuticsApr 22 00:00 ET

3 Cathie Wood Stocks Analysts Like Better Than Tesla

BarchartApr 21 13:15 ET

CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact

TipRanksApr 19 19:31 ET

ChatGPT Stock Predictions: 10 Stocks That Have 10X Potential

Yahoo FinanceApr 19 06:56 ET

Crispr Therapeutics Is Maintained at Buy by Citigroup

Crispr Therapeutics Is Maintained at Buy by Citigroup

Dow JonesApr 18 12:22 ET

Express News | CRISPR Therapeutics AG : Citigroup Raises Target Price to $89 From $88: Citigroup Raises Target Price to $89 From $88

Moomoo 24/7Apr 18 06:36 ET

CRISPR Therapeutics(CRSP.US) Officer Sells US$1.17 Million in Common Stock

$CRISPR Therapeutics(CRSP.US)$ Officer Kulkarni Samarth sold 19,582 shares of common stock on Apr 15, 2024 at an average price of $59.9138 for a total value of $1.17 million.Source: Announcement What

moomoo NewsApr 17 18:28 ET

Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing

Samarth Kulkarni, Director, Chief Executive Officer, on April 15, 2024, sold 19,582 shares in Crispr Therapeutics (CRSP) for $1,173,232. Following the Form 4 filing with the SEC, Kulkarni has control

MT NewswiresApr 17 17:51 ET

Bullish Trendline Has Never Failed Crispr Therapeutics Stock

Schaeffer's Investment ResearchApr 17 12:58 ET

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

Yahoo FinanceApr 16 18:00 ET

Estimating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Key Insights Using the 2 Stage Free Cash Flow to Equity, CRISPR Therapeutics fair value estimate is US$68.64 Current share price of US$58.72 suggests CRISPR Therapeutics is potentially trading close

Simply Wall StApr 16 07:03 ET

TD Cowen Says Sickle Cell Therapies May Get Higher CMS Payments

Seeking AlphaApr 15 16:46 ET

Form 144 | CRISPR Therapeutics(CRSP.US) Officer Proposes to Sell 1.17 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Apr 15, $CRISPR Therapeutics(CRSP.US)$ Officer SAMARTH KULKARNI intends to sell 19,582 shares of its common stock on Apr 15, with a total market value of approximately $1.17 mi

moomoo NewsApr 15 16:30 ET

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune

While it's been said there are no second acts in American life, there can be in American biotech. Vertex Pharmaceuticals is taking a big swing to secure its own second act: Late

Barron'sApr 11 11:00 ET

Express News | Needham Reiterates Buy on CRISPR Therapeutics, Maintains $90 Price Target

Moomoo 24/7Apr 11 06:38 ET